1 / 14

RET Proto- Oncogene in The Development of Thyroid Cancer: Multiple Endocrine Neoplasia Type 2

RET Proto- Oncogene in The Development of Thyroid Cancer: Multiple Endocrine Neoplasia Type 2. Courtney Brooks. Overview. MEN Type 2 RET Gene-Role in Normal Development Normal RET Signaling Pathway Mutations Responsible for MEN Type 2 Mutant RET Signaling Pathway

delu
Download Presentation

RET Proto- Oncogene in The Development of Thyroid Cancer: Multiple Endocrine Neoplasia Type 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. RET Proto- Oncogene in The Development of Thyroid Cancer: Multiple Endocrine Neoplasia Type 2 Courtney Brooks

  2. Overview • MEN Type 2 • RET Gene-Role in Normal Development • Normal RET Signaling Pathway • Mutations Responsible for MEN Type 2 • Mutant RET Signaling Pathway • Diagnosis and Treatment for the Cancer

  3. Multiple Endocrine Neoplasia Type 2 • Thyroid Cancer • Germ line point mutations in RET gene. • Cause over activation of RET • Triggers proliferation in endocrine cells.

  4. 3 Forms of MEN Type 2 • MEN Type 2a • MEN Type 2b • FMTC

  5. RET • Gene on chromosome 10 q 11.2 • Encodes a receptor tyrosine kinase • Required for maturation of nervous system and kidney morphogenesis

  6. RET: Role in Normal Development RET deficient mice : Die shortly after birth Lack the Enteric Nervous System Display Renal Agenesis (no Kidney) Have Fewer Thyroid C Cells

  7. Components of the RET Signaling Pathway • Co-receptors: GFR  1,2, 3, & 4 • Growth Factor Ligands: GDNF, NRTN, ARTN, PSPN

  8. RET Cys GFR  1 Extracellular Domain GDNF Cys Cys Cys Cell Membrane P Intracellular Domain P RAS-RAF Pathway PI3 Kinase Pathway

  9. RET Proto-Oncogene in MEN Type 2 • Germline point mutations of RET are responsible for all Forms of MEN Type MEN 2 • The mutations affect either the extracellular or the intracellular tyrosine kinase domain of RET receptor.

  10. RET Gene Showing Mutations For MEN Type 2

  11. The Effects of Mutations on RET Function • Ligand independent dimerization, activation, and transformation. • Constitutive Phosphorylation of intracellular proteins. • Overactive Signaling

  12. RET Cys GFR  1 Cys Extracellular Domain Arg Cys Cell Membrane P P Intracellular Domain P P Over Active Signalling to Cells Uncontrolled Cell Proliferation

  13. Diagnosis and Management of MEN Type 2 • Genetic Screening for RET mutations • Thyrodectomy • New Therapeutic Strategies : Inhibitors specific for RET oncoproteins

  14. Sources • Albert, L. Carniti, C. RET and NTRK1. 2003. Proto-Oncogenes in Human Diseases. Journal of Cellular Physiology. 195: 168-186 • Manie, S. Santoro, M. 2001. The RET receptor: function in development and dysfunction in congenital malformation. Trends in Genetics. 17 (10): 580-589 • MEN Syndromes. 2000. www.endocrineweb.com/men/men2.html • Borello, MG, Mercalli E. 1995. RET activation by germline MEN 2A, and MEN 2 B mutations. Oncogene 11:2419-2427 • Mulligan LM, et al. Specific mutations of the RET proto-oncogene are related to MEN 2A and FMTC. Nat Genet. 1994; 6(1):70-4

More Related